ArticleChinese journal of integrative medicine2026
Mechanism of Modified Shenqi Pill in Treatment of Allergic Rhinitis Comorbid with Asthma Based on Proteomics.
Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the mechanisms of Modified Shenqi Pill (MSQP) in the treatment of allergic rhinitis comorbid with asthma (ARCA).
methodsAccording to a random number table, 30 BALB/c mice were divided into a control group, an ARCA group, a MSQP low-dose group (MSQP-L, 24.6 g/kg), a MSQP high-dose group (MSQP-H, 49.2 g/kg), and a dexamethasone (DXMS) group (1 mg/kg), with 6 mice in each group. The ARCA mouse model was established using ovalbumin (OVA). MSQP and DXMS were administered by gavage for 10 d. The airway allergic symptom scores, serum OVA-specific immunoglobulin E (OVA-sIgE), histopathological changes in nasal and lung tissues were evaluated. Differential protein expression profiles in lung tissues were detected by proteomics. Functional enrichment analysis of differential proteins was performed using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. Activation of the JAK2/STAT1 signaling pathway was assessed by immunohistochemistry (IHC) and Western blot. Activation of B lymphocytes was detected by CD19 and MHC II immunofluorescence (IF) double staining. The proportions of Th1, Th2, and Th17 cells in lung and spleen tissues were analyzed by flow cytometry.
resultsCompared with the ARCA group, MSQP significantly decreased airway allergic symptom scores and serum OVA-sIgE levels, and reduced eosinophil infiltration and goblet cell hyperplasia in nasal and lung tissues (P<0.05 or P<0.01). GO and KEGG analyses revealed that differential proteins between MSQP and ARCA groups were primarily associated with immune regulation, involving signaling pathways including JAK/STAT, MHC II-mediated antigen presentation, Th1/Th2 differentiation, and Th17 differentiation. Western blot and IHC results showed that MSQP-H reduced the expressions of JAK2, p-JAK2, STAT1, p-STAT1 in nasal and lung tissues (P<0.01). IF results showed that MSQP-H reduced the numbers of CD19
conclusionMSQP improved airway allergic symptoms and inflammatory responses in ARCA mice, possibly by inhibiting the activation of JAK2/STAT1 signaling pathway and B lymphocytes, and correcting imbalances in Th1/Th2 and Th17 differentiation.
Indexed as
Identifiers
42573910What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.